Cargando…

Sequential Therapy of Nadroparin and Rivaroxaban in the Initial Treatment of Patients With Acute Pulmonary Embolism

Background: Sequential low molecular weight heparin (LMWH) plus warfarin, LMWH plus edoxaban, and LMWH plus dabigatran regimens have already shown efficacy and safety in the treatment of acute pulmonary embolism (PE). The efficacy and safety of sequential LMWH plus rivaroxaban regimen in the treatme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiong, Wei, Zhao, Yunfeng, Liu, Song, Du, He, Wang, Yanmin, Li, Wenjie, Guo, Xuejun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988054/ https://www.ncbi.nlm.nih.gov/pubmed/35401221 http://dx.doi.org/10.3389/fphar.2022.810455

Ejemplares similares

Bleeding complications of thromboprophylaxis with dabigatran, nadroparin or rivaroxaban for 6 weeks after total knee arthroplasty surgery: a randomised pilot study
por: van der Veen, Lucia, et al.
Publicado: (2021)

Effects of Routine Antithrombotic-Adjusted Dose of Rivaroxaban and Nadroparin Calcium on Tendon Healing of Rats: An Experimental Study
por: Altun, Suleyman, et al.
Publicado: (2021)

Management of acute pulmonary embolism with sequential hybrid therapy of surgical thrombectomy and rivaroxaban intensive therapy: a case report
por: Migita, Shohei, et al.
Publicado: (2023)

Rivaroxaban for the Treatment of Pulmonary Embolism
por: Vanassche, Thomas, et al.
Publicado: (2013)

Efficacy of rivaroxaban for pulmonary embolism
por: Jia, Juan, et al.
Publicado: (2019)

Massive Spontaneous Haemothorax after Rivaroxaban Therapy for Acute Pulmonary Embolism
por: Yan, Denise Tan, et al.
Publicado: (2019)

Nadroparine calcium or enoxaparine in acute coronary syndrome patients suffering renal insufficiency: The nadroparin versus enoxaparin (NaVe) study design
por: Gurfinkel, Enrique P, et al.
Publicado: (2004)

Rivaroxaban treatment for young patients with pulmonary embolism (Review)
por: Wu, Haidi, et al.
Publicado: (2020)

Current status of rivaroxaban in elderly patients with pulmonary embolism (Review)
por: Song, Zi-Kai, et al.
Publicado: (2020)

Tinzaparin vs. Nadroparin Safety and Efficacy in Neurosurgery
por: Wilhelmy, Florian, et al.
Publicado: (2021)

Effect of Rivaroxaban on Fibrinolytic Therapy in Massive Pulmonary Embolism: Two Cases
por: Kim, Hye-Jin, et al.
Publicado: (2014)

SUSTAINED VENTRICULAR TACHYCARDIA AS AN INITIAL PRESENTATION OF COVID-19 RELATED PULMONARY EMBOLISM DESPITE PREVIOUS RIVAROXABAN THERAPY
por: Mendoza, Juan Alan Fuentes, et al.
Publicado: (2022)

Efficacy and Safety of Rivaroxaban versus Warfarin for the Treatment of Acute Pulmonary Embolism: A Real-World Study
por: Huang, Yan, et al.
Publicado: (2020)

Rivaroxaban versus nadroparin for preventing deep venous thrombosis after total hip arthroplasty following femoral neck fractures: A retrospective comparative study
por: Zhang, Chi, et al.
Publicado: (2018)

Efficacy of rivaroxaban for the treatment of Chinese patients with acute pulmonary embolism: A retrospective study
por: Wang, Lei, et al.
Publicado: (2021)

The Use of Rivaroxaban for Unprovoked Pulmonary Embolism in the Setting of Antithrombin Deficiency
por: Gryn, Oscar J, et al.
Publicado: (2020)

Rivaroxaban Monotherapy in Patients with Pulmonary Embolism: Off-Label vs. Labeled Therapy
por: Di Micco, Pierpaolo, et al.
Publicado: (2022)

Effectiveness and Safety of Nadroparin Therapy in Preterm and Term Neonates with Venous Thromboembolism
por: Sol, Jeanine, et al.
Publicado: (2021)

In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban
por: Wang, Zhi, et al.
Publicado: (2023)

Efficacy and Safety of Nadroparin Calcium-Warfarin Sequential Anticoagulation in Portal Vein Thrombosis in Cirrhotic Patients: A Randomized Controlled Trial
por: Zhou, Ting, et al.
Publicado: (2020)

Direct treatment comparison of DAbigatran and RIvaroxaban versus NAdroparin in the prevention of venous thromboembolism after total knee arthroplasty surgery: design of a randomised pilot study (DARINA)
por: van Veen, Lucia, et al.
Publicado: (2013)

The discovery of rivaroxaban: translating preclinical assessments into clinical practice
por: Kubitza, Dagmar, et al.
Publicado: (2013)

The Function of microRNAs in Pulmonary Embolism: Review and Research Outlook
por: Luo, Mingyao, et al.
Publicado: (2021)

Effect of nadroparin on anti-Xa activity during nocturnal hemodialysis
por: Buitenwerf, Edward, et al.
Publicado: (2015)

Nadroparin calcium: Spontaneous retroperitoneal bleeding: 2 case reports
Publicado: (2022)

Corrigendum: The Function of microRNAs in Pulmonary Embolism: Review and Research Outlook
por: Luo, Mingyao, et al.
Publicado: (2022)

Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect
por: Ing Lorenzini, Kuntheavy, et al.
Publicado: (2016)

Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis
por: Chen, Can, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Rivaroxaban in Chinese Patients With Stable Cardiovascular Disease
por: Feng, Tianyu, et al.
Publicado: (2022)

Antitumor effects of nadroparin combined with radiotherapy in Lewis lung cancer models
por: Zhuang, Xibing, et al.
Publicado: (2018)

The association between pulmonary embolism and the cancer-related genomic alterations in patients with NSCLC
por: Xiong, Wei, et al.
Publicado: (2020)

Rivaroxaban in heart failure patients with left ventricular thrombus: A retrospective study
por: Zhang, Qian, et al.
Publicado: (2022)

An authoritative algorithm most appropriate for the prediction of pulmonary embolism in patients with AECOPD
por: Xiong, Wei, et al.
Publicado: (2020)

Pulmonary embolism and deep vein thrombosis in eosinophilic granulomatosis with polyangiitis successfully treated with rivaroxaban
por: Naito, Tomoyuki, et al.
Publicado: (2018)

Late Pulmonary Embolism after COVID-19 Pneumonia despite Adequate Rivaroxaban Treatment
por: Di Tano, Giuseppe, et al.
Publicado: (2020)

Quantitative Systems Pharmacology Model-Based Predictions of Clinical Endpoints to Optimize Warfarin and Rivaroxaban Anti-Thrombosis Therapy
por: Hartmann, Sonja, et al.
Publicado: (2020)

Evaluation of Herb–Drug Interaction Between Danshen and Rivaroxaban in Rat and Human Liver Microsomes
por: Wang, Xu, et al.
Publicado: (2022)

Rare complication of nadroparin injections: Skin necrosis and heparin‐induced thrombocytopenia syndrome
por: Malinauskiene, Laura, et al.
Publicado: (2022)

Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID‐19 intensive care unit patients
por: Romano, Lorenzo G. R., et al.
Publicado: (2022)

Localized and Generalized Skin Adverse Drug Reactions to Nadroparin Calcium Injection in 6 Cases of Pregnant Women
por: Chen, Ting, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r1c3cej6kfh8vipeddasqpfhgu